eISSN: 2449-9315
ISSN: 1234-8279
Pharmacotherapy in Psychiatry and Neurology/Farmakoterapia w Psychiatrii i Neurologii
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
vol. 38
Review article

The effect of psychotropic drugs on the occurrence and course of COVID-19

Janusz Rybakowski

Department of Adult Psychiatry, Poznan University of Medical Sciences, Poznan, Poland;
Klinika Psychiatrii Dorosłych, Uniwersytet Medyczny w Poznaniu, Poznań, Polska
Farmakoterapia w Psychiatrii i Neurologii 2022, 38 (1), 9–21
Online publish date: 2022/08/02
Article file
Get citation
JabRef, Mendeley
Papers, Reference Manager, RefWorks, Zotero
PlumX metrics:
1. Amsterdam JD, García-España F, Rybakowski J. Rates of flu-like infection in patients with affective illness. J Affect Disord 1998: 177-182.
2. Bonnet U, Juckel G. COVID-19 outcomes: Does the use of psychotropic drugs make a difference? Accumulating evidence of a beneficial effect of antidepressants-a scoping review. J Clin Psychopharmacol 2022; 42: 284-292.
3. Brenner SR. The potential of memantine and related adamantanes such as amantadine, to reduce the neurotoxic effects of COVID-19, including ARDS and to reduce viral replication through lysosomal effects. J Med Virol 2020; 92: 2341-2342.
4. Butler M, Cross B, Hafeez D, Lim MF, Morrin H, Rengasamy ER et al. Emerging knowledge of the neurobiology of COVID-19. Psychiatr Clin North Am 2022; 45: 29-43.
5. Canal-Rivero M, Catalán-Barragán R, Rubio-García A, Garrido-Torres N, Crespo-Facorro B, Ruiz-Veguilla M; IBIS Translational Psychiatry Group. Lower risk of SARS-CoV-2 infection in individuals with severe mental disorders on antipsychotic treatment: A retrospective epidemiological study in a representative Spanish population. Schizophr Res 2021; 229: 53-54. (a)
6. Canal-Rivero M, Catalán-Barragán R, Rubio-García A, Garrido-Torres N, Crespo-Facorro B, Ruiz-Veguilla M; IBIS Translational Psychiatry Group. The role of antipsychotics against COVID-19: A topic for debate. Schizophr Res 2021; 235: 5-6. (b)
7. Clelland CL, Ramiah K, Steinberg L, Clelland JD. Analysis of the impact of antidepressants and other medications on COVID-19 infection risk in a chronic psychiatric in-patient cohort. BJPsych Open 2021; 8: e6.
8. Collazos J, Domingo P, Fernández-Araujo N, Asensi-Díaz E, Vilchez-Rueda H, Lalueza A et al. Exposure to valproic acid is associated with less pulmonary infiltrates and improvements in diverse clinical outcomes and laboratory parameters in patients hospitalized with COVID-19. PLoS One 2022; 17: e0262777.
9. Cortés-Borra A, Aranda-Abreu GE. Amantadine in the prevention of clinical symptoms caused by SARS-CoV-2. Pharmacol Rep 2021 Jun; 73(3): 962-965.
10. Dalwadi DA, Kim S, Schetz JA. Activation of the sigma-1 receptor by haloperidol metabolites facilitates brain-derived neurotrophic factor secretion from human astroglia. Neurochem Int 2017; 105: 21-31.
11. De Picker LJ, Leboyer M, Geddes JR, Morrens M, Harrison PJ, Taquet M. Association between serum lithium level and incidence of COVID-19 infection. Br J Psychiatry 2022 Mar 23: 1-3; doi: 10.1192/bjp.2022.42. Online ahead of print.
12. Dechaumes A, Nekoua MP, Belouzard S, Sane F, Engelmann I, Dubuisson J et al. Fluoxetine can inhibit SARS-CoV-2 in vitro. Microorganisms 2021; 9: 339.
13. Facente SN, Reiersen AM, Lenze EJ, Boulware DR, Klausner JD. Fluvoxamine for the early treatment of SARS-CoV-2 infection: A review of current evidence. Drugs 2021; 81: 2081-2089.
14. Fillmore N, Bell S, Shen C, Nguyen V, La J, Dubreuil M et al. Disulfiram use is associated with lower risk of COVID-19: A retrospective cohort study. PLoS One 2021; 16: e0259061.
15. Fink K, Nitsche A, Neumann M, Grossegesse M, Eisele KH, Danysz W. Amantadine inhibits SARS-CoV-2 in vitro. Viruses 2021; 13: 539.
16. Gattner K, Rybakowski J. Ciężki przebieg COVID-19 u pacjenta leczonego profilaktycznie litem. Farmakoter Psychiatr Neurol 2020; 36: 143-148.
17. Gorostowicz A, Dudek D, Siwek M. List do redakcji. Terapia litem jako czynnik chroniący przed zakażeniem wirusem SARS-CoV-2? Obserwacje z ogniska epidemicznego Psychiatr Pol 2022; 56: 417-422.
18. Hashimoto K. Repurposing of CNS drugs to treat COVID-19 infection: targeting the sigma-1 receptor. Eur Arch Psychiatry Clin Neurosci 2021; 271: 249-258.
19. Hashimoto Y, Suzuki T, Hashimoto K. Old drug fluvoxamine, new hope for COVID-19. Eur Arch Psychiatry Clin Neurosci 2022; 272: 161-163.
20. Hoertel N, Sánchez-Rico M, Vernet R, Jannot AS, Neuraz A, Blanco C et al. Observational study of chlorpromazine in hospitalized patients with COVID-19. Clin Drug Investig 2021; 41: 221-233. (a)
21. Hoertel N, Sánchez-Rico M, Vernet R, Jannot AS, Neuraz A, Blanco C et al. Observational study of haloperidol in hospitalized patients with COVID-19. PLoS One 2021; 16: e0247122. (b)
22. Hoertel N, Sánchez-Rico M, Vernet R, Beeker N, Jannot AS, Neuraz A et al. Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study. Mol Psychiatry 2021; 26: 5199-5212. (c)
23. Jaracz J, Rybakowski J. Fluwoksamina – najdłużej stosowany lek z grupy selektywnych inhibitorów wychwytu serotoniny. Farmakoter Psychiatr Neurol 2006; 22: 167-175.
24. Kessler RC, Chiu WT, Hwang IH, Puac-Polanco V, Sampson NA, Ziobrowski HN et al. Changes in prevalence of mental Illness among US adults during compared with before the COVID-19 pandemic. Psychiatr Clin North Am 2022; 45: 1-28.
25. Koenders M, Mesbah R, Spijker A, Boere E, de Leeuw M, van Hemert B et al. Effects of the COVID-19 pandemic in a preexisting longitudinal study of patients with recently diagnosed bipolar disorder: Indications for increases in manic symptoms. Brain Behav 2021; 11: e2326.
26. Kurczewska E, Nawojczyk M, Ferensztajn-Rochowiak E, Jaracz J, Rybakowski F. Onset of bipolar disorder induced by treated COVID-19 infection in a 44-year-old man with no psychiatric history. Bipolar Disord 2022 Mar; 24(2): 214-216.
27. Lee TC, Vigod S, Bortolussi-Courval É, Hanula R, Boulware DR, Lenze EJ et al. Fluvoxamine for outpatient management of COVID-19 to prevent hospitalization: A systematic review and meta-analysis. JAMA Netw Open 2022; 5: e226269.
28. Lenze EJ, Mattar C, Zorumski CF, Stevens A, Schweiger J, Nicol GE et al. Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: A randomized clinical trial. JAMA 2020; 324: 2292-2300.
29. Lenze EJ, Reiersen AM, Santosh PJ. Repurposing fluvoxamine, and other psychiatric medications, for COVID-19 and other conditions. World Psychiatry 2022; 21: 314-315.
30. Lieb J. Remission of recurrent herpes infection during therapy with lithium. N Eng J Med 1979; 301: 942.
31. Malinowska B, Baranowska-Kuczko M, Kicman A, Schlicker E. Opportunities, challenges and pitfalls of using cannabidiol as an adjuvant drug in COVID-19. Int J Mol Sci 2021; 22: 1986.
32. Mazza MG, Zanardi R, Palladini M, Rovere-Querini P, Benedetti F. Rapid response to selective serotonin reuptake inhibitors in post-COVID depression. Eur Neuropsychopharmacol 2022; 54: 1-6.
33. Moreno-Pérez O, Merino E, Ramos JM, Rodríguez JC, Diaz C, Mas P et al. Valproic acid could help in the fight against COVID-19: a case-control study. Neurologia 2022 Feb 14; doi: 10.1016/j.nrl.2022.01.007. Online ahead of print.
34. Mueller JK, Riederer P, Müller WE. Neuropsychiatric drugs against COVID-19: what is the clinical evidence? Pharmacopsychiatry 2022; 55: 7-15.
35. Murru A, Manchia M, Hajek T, Nielsen RE, Rybakowski JK, Sani G et al. Lithium’s antiviral effects: a potential drug for COVID-19 disease? Int J Bipolar Disord 2020; 8: 21.
36. Nemani K, Williams SZ, Olfson M, Leckman-Westin E, Finnerty M, Kammer J et al. Association between the use of psychotropic medications and the risk of COVID-19 infection among long-term inpatients with serious mental illness in a New York State-wide psychiatric hospital system. JAMA Netw Open 2022; 5: e2210743.
37. Nguyen LC, Yang D, Nicolaescu V, Best TJ, Gula H, Saxena D et al. Cannabidiol inhibits SARS-CoV-2 replication through induction of the host ER stress and innate immune responses. Sci Adv. 2022 Feb 25; 8: eabi6110. doi: 10.1126/sciadv.abi6110. Epub ahead of print.
38. Nowak JK, Walkowiak J. Lithium and coronavirus infections. A scoping review. F1000Research 2020; 9: 93.
39. Qaswal AB, Guzu H, Suleiman A, Atiyat B. The potential role of lithium as an antiviral agent against SARS-CoV-2 via membrane depolarization: review and hypothesis. Sci Pharm 2021; 89; 11.
40. Pardamean E, Roan W, Iskandar KTA, Prayangga R, Hariyanto TI. Mortality from coronavirus disease 2019 (COVID-19) in patients with schizophrenia: A systematic review, meta-analysis and meta-regression. Gen Hosp Psychiatry 2022; 75: 61-67.
41. Park MH, Kwon DY. A retrospective review of memantine use and COVID-19-associated mortality from a national database. J Med Virol 2021; 93: 168-169.
42. Pitt B, Sutton NR, Wang Z, Goonewardena SN, Holinstat M. Potential repurposing of the HDAC inhibitor valproic acid for patients with COVID-19. Eur J Pharmacol 2021; 898: 173988.
43. Plaze M, Attali D, Prot M, Petit AC, Blatzer M, Vinckier F et al. Inhibition of the replication of SARS-CoV-2 in human cells by the FDA-approved drug chlorpromazine. Int J Antimicrob Agents 2021; 57: 106274.
44. Rajkumar RP. Lithium as a candidate treatment for COVID-19: Promises and pitfalls. Drug Dev Res 2020; 81: 782-785.
45. Ramlall V, Zucker J, Tatonetti N. Melatonin is significantly associated with survival of intubated COVID-19 patients. medRxiv 2020: 2020.10.15.20213546.
46. Reis G, Dos Santos Moreira-Silva EA, Silva DCM, Thabane L, Milagres AC, Ferreira TS et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. Lancet Glob Health 2022; 10: e42-e51.
47. Rejdak K, Fiedor P, Bonek R, Goch A, Gala-Błądzińska A, Chełstowski W et al. The use of amantadine in the prevention of progression and treatment of COVID-19 symptoms in patients infected with the SARS-CoV-2 virus (COV-PREVENT): Study rationale and design. Contemp Clin Trials 2022; 116: 106755.
48. Rudd CE. Commentary: Does lithium deserve a place in the treatment against COVID-19? A preliminary observational study in six patients, case report. Front Pharmacol 2020; 11: 613734. (b)
49. Rudd CE. GSK-3 inhibition as a therapeutic approach against SARs CoV2: Dual benefit of inhibiting viral replication while potentiating the immune response. Front Immunol 2020; 11: 1638. (a)
50. Rybakowski J. Informacja dotycząca stosowania litu w okresie pandemii COVID-19. Psychiatra 2020; 28: 48-49.
51. Rybakowski J. Występowanie zakażenia COVID-19 u 50 pacjentów otrzymujących lit. Farmakoter Psychiatr Neurol 2021; 37: 113-121.
52. Rybakowski JK, Amsterdam JD. Lithium prophylaxis and recurrent labial herpes infections. Lithium 1991; 2: 43-47.
53. Sabe M, Dorsaz O, Huguelet P, Kaiser S. Toxicity of psychotropic drugs in patients with COVID-19: A systematic review. Gen Hosp Psychiatry 2021; 70: 1-9
54. Sánchez-Rico M, Limosin F, Vernet R, Beeker N, Neuraz A, Blanco C et al. Hydroxyzine use and mortality in patients hospitalized for COVID-19: A multicenter observational study. J Clin Med 2021;10: 5891.
55. Skinner G.R.B., Hartley C., Buchan A., Harper L, Gallimore P. The effect of lithium chloride on the replication of herpes simplex virus. Med Microbiol Immunol 1980; 168: 258-265.
56. Spuch C, López-García M, Rivera-Baltanás T, Rodrígues-Amorím D, Olivares JM. Does lithium deserve a place in the treatment against COVID-19? A preliminary observational study in six patients, case report. Front Pharmacol 2020; 11: 557629.
57. Suwanwongse K, Shabarek N. Lithium toxicity in two coronavirus disease 2019 (COVID-19) patients. Cureus 2020; 12: e8384.
58. Szkaradkiewicz A. Nowe koronawirusy człowieka – SARS-CoV, MERS-CoV i 2019-nCoV (COVID-19). Zakażenia XXI Wieku 2020; 1: 1.
59. Wen W, Chen C, Tang J, Wang C, Zhou M, Cheng Y et al. Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19: a meta-analysis. Ann Med 2022; 54: 516-523.
60. Wichniak A, Kania A, Siemiński M, Cubała WJ. Melatonin as a potential adjuvant treatment for COVID-19 beyond sleep disorders. Int J Mol Sci. 2021; 22: 8623.
61. Zhang R, Wang X, Ni L, Di X, Ma B, Niu S et al. COVID-19: Melatonin as a potential adjuvant treatment. Life Sci 2020; 250: 117583.
Quick links
© 2023 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.